Stockscreener 앱 받기
5.96
4.03%
-0.25
시간 외 거래:
6.00
0.04
+0.67%
전일 마감가:
$6.21
열려 있는:
$6.26
하루 거래량:
181.84K
Relative Volume:
0.73
시가총액:
$164.11M
수익:
$61.86M
순이익/손실:
$-11.43M
주가수익비율:
-12.37
EPS:
-0.4818
순현금흐름:
$-12.52M
1주 성능:
-5.85%
1개월 성능:
+18.25%
6개월 성능:
-20.11%
1년 성능:
-12.61%
1일 변동 폭
$5.915
$6.31
1주일 범위
$5.915
$6.55
52주 변동 폭
$4.31
$9.555
Journey Medical Corp Stock (DERM) Company Profile
명칭
Journey Medical Corp
전화
480-434-6670
주소
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Compare DERM vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DERM
Journey Medical Corp
|
5.96 | 170.99M | 61.86M | -11.43M | -12.52M | -0.4818 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-25 | 개시 | H.C. Wainwright | Buy |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | ROTH MKM | Buy |
| 2021-12-07 | 개시 | B. Riley Securities | Buy |
Journey Medical Corp 주식(DERM)의 최신 뉴스
Best travel insurance if you have a medical condition 2026 - which.co.uk
Journey Medical CEO to join A.G.P. Virtual Healthcare Conference fireside chat on May 20, 2026 - Pluang
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference - The Manila Times
Journey Medical Corp stock (US48113J1007): dermatology player in focus after recent financing update - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
Journey Medical Corporation (NASDAQ:DERM) Q1 2026 Earnings Call Transcript - Insider Monkey
Journey Medical Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Analyst Reiterates Buy on Journey Medical, Maintains $13 Price Target After Strong 1Q26 and Emrosi Momentum - TipRanks
Journey Medical Corp stock (US48113J1007): Q1 revenue jumps 21% to $16M - AD HOC NEWS
Journey Medical Corp (DERM) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Here's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings - Yahoo Finance
Earnings call transcript: Journey Medical Q1 2026 reports strong EPS beat - Investing.com
Journey Medical Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Journey Medical Q1 2026 shows strong revenue growth - Investing.com
Transcript: Journey Medical Q1 2026 Earnings Conference Call - Benzinga
Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Journey Medical earnings beat by $0.05, revenue fell short of estimates - Investing.com
Journey Medical Corp (NASDAQ:DERM) Slightly Misses Q1 2026 Revenue Expectations as Stock Rises on Strong Emrosi Growth and Full-Year Profitability Outlook - ChartMill
Journey Medical (NASDAQ: DERM) grows Q1 2026 revenue 21% but remains unprofitable - Stock Titan
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Journey Medical (Nasdaq: DERM) posts 21% Q1 2026 revenue growth - Stock Titan
Rosacea pill Emrosi powers Journey Medical’s 21% Q1 revenue jump - Stock Titan
Assertio (ASRT) moves 17.0% higher: Will this strength last? - MSN
TradingKey - tradingkey.com
Journey Medical Corp expected to post a loss of 8 cents a shareEarnings Preview - TradingView
DERM Stock Price, Quote & Chart | JOURNEY MEDICAL CORP (NASDAQ:DERM) - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in FS KKR Capital Corp. of Class Action Lawsuit and Upcoming DeadlinesFSK - PR Newswire
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 - GlobeNewswire
Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
AIROS Medical Introduces ARTAIRA Travel Case to Support Therapy Continuity for PAD Patients - PR Newswire
Journey Medical (DERM) Expected to Announce Earnings on Wednesday - MarketBeat
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last? - Yahoo Finance
Fortress Biotech CEO to speak at royalty company virtual conference - Stock Titan
BioHarvest Chief Medical Officer Shares Personal Journey at Collision Conference - TMX Newsfile
MSN Money - MSN
10 Best Travel Insurance Companies For 2026 - Forbes
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical CorporationDERM - ChartMill
Journey Medical (NASDAQ: DERM) details 2026 virtual meeting, board and pay - Stock Titan
Vanguard reports 1.21M-share stake in Journey Medical Corp (DERM) - Stock Titan
FBIO Stock Price, Quote & Chart | FORTRESS BIOTECH INC (NASDAQ:FBIO) - ChartMill
Q1 EPS Estimates for Journey Medical Cut by HC Wainwright - MarketBeat
Journey Medical Corporation (NASDAQ:DERM) Receives Average Rating of "Hold" from Analysts - MarketBeat
Journey Medical (DERM) COO receives new RSU and option grants - Stock Titan
Journey Medical (DERM) CFO receives new RSU and stock option grants - Stock Titan
Journey Medical (DERM) CEO granted RSUs and stock options - Stock Titan
Q4 EPS Estimates for Journey Medical Raised by HC Wainwright - MarketBeat
Journey Medical Expands Emrosi™ Coverage to Over 150 Million Commercial Lives with Third Major GPO Contract - Minichart
DERM Financials: Income Statement, Balance Sheet & Cash Flow | Journey Medical Corp - Stock Titan
Journey Medical Expands Emrosi Commercial Access Across U.S. - TipRanks
Journey Medical expands Emrosi payer access to 85% of US commercial lives - TradingView
Emrosi access reaches 85% of U.S. commercial lives at Journey Medical (Nasdaq: DERM) - Stock Titan
Journey Medical Corp (DERM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.92%
4.44%
자본화:
|
볼륨(24시간):